Quantum Cyber N.V.
Close on Oct 19, 2026
- Market cap
- $19.10M
- P/E (TTM)
- –
- Dividend yield
- –
About Quantum Cyber
Pharmaceutical Preparations, SIC 2834
Mainz Biomed N.V., operating as Quantum Cyber, is a molecular diagnostics company focused on developing in-vitro diagnostic solutions for cancer detection while expanding into post-quantum cybersecurity. Its primary research and clinical development efforts target non-invasive screening tools for pancreatic cancer, notably a blood-based test employing licensed mRNA biomarkers with proprietary artificial intelligence algorithms, alongside an early-stage stool-based candidate called PancAlert. The company historically commercialized ColoAlert, an at-home colorectal cancer diagnostic kit, and developed related screening technologies before divesting those assets to prioritize pancreatic cancer diagnostics.
Headquartered in Mainz, Germany, the company conducts development and previously manufactured test kits at its local German facility. As of March 30, 2026, its workforce comprised approximately ten full-time and three part-time employees. Originally established under Dutch corporate law, the business serves international healthcare markets and clinical research partners through its specialized European operational base.
Summary of the business section of Quantum Cyber's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Quantum Cyber N.V.
- Founded
- 2021
- Headquarters
- Mainz, Germany
- Address
- Robert Koch Strasse 50
- Phone
- 49 6131 5542860
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- Reliant CPA PC, Newport Beach, CA
Stock & identifiers
- Ticker
- QUCY
- Exchange
- Nasdaq
- IPO date
- Nov 5, 2021
- Shares outstanding
- 84M, Aug 13, 2026
- Public float
- $5.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-40 reverse, Mar 31, 2025
- SEC CIK
- 1874252
- CUSIP
- N5436L119
- ISIN
- USN5436L1191
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David E. Lazar | Chief Executive Officer, Director | 9,000,000 |
| Guido Baechler | Chief Executive Officer, Director | 605,058 |
| William J. Caragol | Chief Financial Officer | 367,899 |
| Louis R. Buffalino | Director | 0 |
| Peter O'Rourke | Director | 0 |
| David Natan | Director | 137,141 |
| Avraham Ben-Tzvi | Director | 252,000 |
| Heinrich Dreismann | Director | 64,700 |
| Gregory J. Tibbitts | Director | 55,875 |
| Hans Hekland | Director | 45,000 |
Employees
Headcount reported in annual reports
“had approximately 10 full-time and 3 part-time employees as of March 30, 2026.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 16, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 26, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 15, 2026 | Name change | Name changed from MAINZ BIOMED N.V. to Quantum Cyber N.V. |
| Mar 25, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 2, 2022 | Late filing | Notification of late filing |
| Nov 12, 2021 | Name change | Name changed from Mainz Biomed B.V. to MAINZ BIOMED N.V. |
| Nov 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |